Physician profile
Peter Hanna
NPI 1780875104
$4,576.73
in general payments reported to CMS, 2019-2025
30 companies · $791 in 2025
The $791 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $475 · 2020: $607 · 2021: $723 · 2022: $833 · 2023: $497 · 2024: $651 · 2025: $791.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,939.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,938.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $913.71 | 2019-2025 | Repatha, Otezla, Evenity |
| Astrazeneca Pharmaceuticals Lp | $714.52 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbott Laboratories | $516.66 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Abbvie INC. | $401.34 | 2021-2025 | |
| Pfizer INC. | $324.72 | 2019-2025 | |
| Glaxosmithkline, LLC. | $257.75 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $195.72 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $148.61 | 2019-2024 | Xarelto |
| Lilly USA, LLC | $132.21 | 2019-2025 | Mounjaro |
| Novartis Pharmaceuticals Corporation | $110.46 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $90.90 | 2019-2023 | Trulance, Xifaxan |
| Astellas Pharma US INC | $78.20 | 2019-2025 | Veozah |
| Merck Sharp & Dohme LLC | $76.85 | 2019-2024 | Gardasil 9, Capvaxive, Gardasil |
| Bayer Healthcare Pharmaceuticals INC. | $69.54 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.80 | 2019-2024 | Jardiance |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $60.69 | 2023-2024 | Senza |
| Boston Scientific Corporation | $58.15 | 2019-2022 | |
| Exact Sciences Corporation | $54.89 | 2024-2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $44.41 | 2025 | Caplyta |
| Sanofi Pasteur INC. | $42.92 | 2023 | |
| Eisai INC. | $40.50 | 2025 | |
| Nestle Healthcare Nutrition INC. | $32.46 | 2022-2023 | |
| Almatica Pharma LLC | $21.89 | 2023 | Loreev Xr |
| Sumitomo Pharma America, INC. | $21.62 | 2023 | Gemtesa |
| Ascensia Diabetes Care US INC. | $20.55 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.16 | 2022 | |
| Sanofi-Aventis U.S. LLC | $17.61 | 2022 | |
| Cranial Technologies, INC | $16.39 | 2020 | |
| Allergan, INC. | $14.46 | 2020 | |
| Ironwood Pharmaceuticals, INC | $13.04 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Hanna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.